Beta 2 adrenoceptor agonists are very effective in the treatment of acute asthma symptoms.
ence (95% CI) −1.7 (−3.0 to −0.4) doub-High doses of glucocorticosteroid prevent and ling dilutions) but not to methacholine reverse 2 receptor tolerance in desensitised (mean difference −0.1 (−1.0 to 0.8) doub-animals and in human tissue in vitro. 6 Studies ling dilutions). Single high dose budeson-in both asthmatic and non-asthmatic subjects ide increased the protective effect of using high dose glucocorticosteroids have terbutaline more to AMP than to metha-shown that glucocorticosteroids rapidly reverse choline challenge (+0.76 (0.3) doubling 2 adrenoceptor tolerance of lymphocytes, dilutions compared with +0.13 (0.4) doub-neutrophils, and normal airways. 5 Thus, high ling dilutions, respectively). The mean dose inhaled glucocorticosteroids would be expected to reverse loss of bronchoprotection in (SE) difference between budesonide and asthma induced by 2 agonists.
5 placebo for methacholine challenge was Prolonged treatment with steroids in vivo 0.08 (0.14) whereas that for AMP was 0. 075 has direct inhibitory effects on mast cells, with (0.15); p=NS. The difference in PC 20 ical placebo in a single dose exactly 12 hours before challenge. Terbutaline treatment was continued between the challenges (with terbutaline being taken immediately after the chal-AMP challenge. 10 Investigating the effect of a single dose of glucocorticosteroid in vivo should lenge) on the assumption that any tolerance would, if anything, be greater after a longer therefore allow study of mast cell 2 adrenoceptor rather than mast cell function in treatment period. There was a minimum 10 day washout period between treatment periods clinical asthma.
We have therefore investigated the effect of and the study sequence was then repeated with the alternative inhaler. Inhaled ipratropium a single high dose of budesonide on terbutaline induced loss of bronchoprotection. Budesonide bromide and caffeinated beverages were withheld for at least 12 hours before each challenge. or identical placebo were administered after 10 days of regular therapy with terbutaline and mast cell and smooth muscle effects were measured by assessment of the response to AMP    Bronchial provocation challenge was perand methacholine, respectively.
formed as previously reported. 4 Fresh solutions of methacholine and AMP (Sigma, Poole, UK) were made up in 0.9% saline in doubling diMethods  lutions (0.06-32mg/ml and 0.39-800mg/ml, respectively). Each solution was administered Seventeen non-smoking subjects with mild asthma were recruited (table 1). All consented from a nebuliser attached to a breath activated dosimeter (Mefar, Brescia, Italy). After resting to participate in the study which was approved by the local ethics committee. All subjects had quietly, baseline spirometric values were assessed by three forced expiratory manoeuvres asthma according to the criteria of the American Thoracic Society. Baseline forced ex-using a dry wedge spirometer (Vitalograph, Buckingham, UK). Terbutaline 500 g was adpiratory volume in one second (FEV 1 ) for all subjects was >70% predicted. All subjects were ministered via a Turbohaler and FEV 1 measured in an identical manner 15 minutes sensitive to methacholine and AMP challenge as documented by a provocative concentration afterwards. Subjects then inhaled five breaths of saline followed by incremental doses of causing a 20% fall in FEV 1 (PC 20 ) of <8mg/ ml and <100mg/ml, respectively, at screening methacholine or AMP at three minute intervals.
Challenges were terminated when a 20% de-(table 1). None had suffered an asthma exacerbation or upper respiratory tract infection crease in FEV 1 from the post-saline value was reached. within six weeks preceding the study, nor used any glucocorticosteroid within two months. All used inhaled short acting 2 agonists for asthma control, but ipratropium bromide was sub-  All values were expressed as mean (SE) apart stituted during the study.
from PC 20 results which were expressed as geometric means. Log dose-response curves were constructed and PC 20 calculated by linear   The study was double blind, randomised, interpolation. Baseline FEV 1 , post-bronchodilator FEV 1 , and log PC 20 values were complacebo controlled, and crossover. Due to potential interaction, methacholine and AMP pared by repeated measures two-way analysis of variance (ANOVA) with Bonferroni's corchallenges were conducted on separate days with the order of challenge randomised on rection for multiple comparisons. A standardised computerised statistical package entry into the study but remaining identical for each patient throughout the study, and (NCSS) was used for the analysis. All tests of significance were two-tailed and p values of performed at an identical time of day for each patient. The power of the study was calculated <0.05 were regarded as significant.
The effect of treatment on responses to proon the basis of variation of PC 20 values as performed in our laboratory.
2 With an value vocation on each challenge day was calculated by comparing the difference in PC 20 before and of 5% and power of 80% it was calculated that 15 patients would be required to detect a after terbutaline treatment and also after the group.bmj.com on June 30, 2017 -Published by http://thorax.bmj.com/ Downloaded from administration of the budesonide and placebo and, in particular, between the pre-terbutaline and post-terbutaline treatment values (3.35 in each subject; this was expressed as doubling doses using the formula: (log PC 20 after (0.11) l versus 3.38 (0.11) l; p=NS). budesonide -log PC 20 after placebo)/log 10 2). 4 The response to budesonide and placebo for each challenge was calculated taking the post-        terbutaline values as baseline, and differences between pre-terbutaline and post-terbutaline Changes in methacholine PC 20 and AMP reactivity were +0.13 (0.4) and +0.76 (0.3) treatment periods were analysed for each treatment period individually.
doubling dilutions, respectively, on budesonide and +0.51 (0.4) and +0.6 (0.2) doubling dilutions on placebo (fig 1) . Compared with placebo, budesonide had no statistically sigResults Two patients were withdrawn from the study nificant effect on either methacholine or AMP challenge. The mean difference between due to upper respiratory tract infections. Their results were excluded from the statistical ana-budesonide and placebo for methacholine challenge was 0.08 (0.14) whereas that for AMP lysis.
was 0.075 (0.15). This difference between challenge agents was not statistically significant.             1 Discussion Little information is available regarding the Baseline geometric mean PC 20 prior to regular treatment and without any terbutaline to effect of glucocorticosteroids on bronchoprotective tolerance in asthma. We have inmethacholine was −0.27 log units and to AMP was 1.12 log units.
vestigated whether such tolerance could be readily restored by inhaled glucocorticosteroids After treatment with terbutaline for seven days the mean log PC 20 to methacholine and whether this is mediated by reversal of mast cell 2 adrenoceptor function. changed from 0.34 log units to 0.31 (mean difference (95% CI) −0.1 (−1.0 to 0.8) doubMany studies using both human and animal pulmonary and bronchial tissue have previously ling dilutions); this small change was not statistically significant (fig 1) . With AMP, however, demonstrated reversal of 2 adrenergic tolerance by glucocorticosteroids. 5 9 Glucomean log PC 20 changed from 1.56 to 1.07 log units (mean difference (95% CI) −1.7 (−3.0 corticosteroids also prevent desensitisation of the receptor and restore downregulated reto −0.4 doubling dilutions; p<0.05). The difference in loss of bronchoprotection between ceptors to near normal levels. 5 6 In normal airways 2 adrenergic resistance induced by the two challenge agents was statistically significant (p<0.04). regular inhaled 2 agonist therapy can be restored by the use of intravenous hydrocortisone Baseline FEV 1 was 85 (2.6)% predicted. Terbutaline caused significant bronchodilatation when measured between six and 48 hours and lymphocyte 2 adrenoceptor function and numwhich was only minimally less after the terbutaline treatment period (8.4% versus 6.6%; ber can be restored to normal within 16 hours by oral or intravenous high dose glucop=NS). No significant change in baseline FEV 1 was observed at any of the study visits corticosteroids. 5 We therefore expected that a single high dose of budesonide would restore mast cell 2 adrenoceptor function. In our study bronchoprotective tolerance occurred to AMP challenge, but not to methacholine. We failed to demonstrate significant reversal of bronchoprotective tolerance with single dose inhaled budesonide, implying that mast cell 2 adrenoceptor function is not readily reversed by single dose glucocorticosteroids when used in maximal recommended dosage. Whether an intravenous dose or one exceeding the recommended dosage might have been effective is uncertain. Steroid concentrations used in laboratory studies have been considerably higher than those used clinically, but we wished to study an effect which could reflect the situation in an asthmatic patient. Regular inhaled glucocorticosteroids, although more clinically applicable, could not be used in view of their 
